What endometrial cancer or bleeding risks come with bioidentical progesterone?

The short version: bioidentical progesterone protects the uterine lining when paired with estrogen, but the evidence here is thin on long-term cancer outcomes and does not settle the bleeding question.

The core mechanism is straightforward. Estrogen alone makes the uterine lining grow, which raises endometrial cancer risk. Progesterone opposes that growth and triggers shedding, which is why any woman with a uterus taking estrogen needs it [1]. The REPLENISH trial, a phase 3 study of an estradiol plus natural progesterone capsule, was designed to check endometrial safety by biopsy, targeting a hyperplasia rate at or below 1 in 100 women [1]. That is the right question, and it is a hard clinical endpoint, not a surrogate. But the trial was funded by the manufacturer, and the full safety results are not in this retrieval, only the design.

The bleeding picture is more complicated. Progesterone can cause breakthrough bleeding, especially in the first months, and the retrieved evidence does not give a clean rate for bioidentical progesterone specifically. One 2026 study of intravaginal progesterone for adenomyosis, a condition where uterine tissue grows into the muscle wall, actually reduced abnormal bleeding, with median severity scores dropping from 8 to 6 on a 10-point scale [2]. That is a different population than a healthy woman on menopausal hormone therapy, so it does not transfer directly. The same study had no control group, which limits what it can prove [2].

What the retrieval cannot see matters more than what it shows. No study here tracks endometrial cancer rates over years of bioidentical progesterone use. No study compares it head-to-head against synthetic progestins on cancer or bleeding outcomes. The manufacturer-funded trial design exists [1], but the long-term data is simply absent from these records. Absence of evidence is not evidence of safety.

My call: bioidentical progesterone is mechanistically sound for protecting the uterine lining against estrogen-driven cancer, and the short-term bleeding data is mixed, but no long-term cancer outcome data appears in this retrieval. Confidence: low.